期刊文献+

新型抗菌剂:脂烯酰基酰基载体蛋白还原酶抑制剂的研究进展 被引量:1

Progress in Enoyl-[acyl-carrier-protein] Reductase Inhibitors,a Novel Type of Antibacterial Agents
下载PDF
导出
摘要 简介脂烯酰基酰基载体蛋白还原酶在脂肪酸生物合成中的催化作用,综述其5类抑制剂即1,4-二取代咪唑类、2,9-二取代-1,2,3,4-四氢吡啶并[3,4-b]吲哚类、氨基吡啶类、吲哚萘啶酮类及3-氰基-4,6-二取代-2-吡啶硫醚类化合物的抗菌作用机制和构效关系。脂肪酸合成途径Ⅱ是大多数原核生物(如细菌)合成脂肪酸的方式,脂烯酰基酰基载体蛋白还原酶是催化细菌脂肪酸合成循环中最终步骤的酶,研究开发作用于该酶的抑制剂有可能发现新型抗菌药物。 The catalyzing of enoyl-[acyl-carrier-protein] reductase Ⅰ (FabI) in the biosynthesis of fatty acid was briefly introduced. The mechanism of antibacterial action and structure-activity relationship of five kinds of FabI inhibitors, i.e., 1,4-disubstituted imidazoles, 2, 9-disubstituted-1,2, 3,4-tetrahydropyrido [ 3,4-b ] indoles, aminopyridines, indole naphthyridinones and 3-cyano-4, 6-disubstituted-2-pyridylthioethers, were reviewed. Fatty acid synthesis Ⅱ (FAS Ⅱ ) is the biosynthetic pathway for fatty acid in most prokaryotes, such as bacteria. FabI is the enzyme which catalyzes the ultimate step in bacterial FAS Ⅱ . Therefore the research and development of its inhibitors are helpful to the discovery of novel antibacterials.
出处 《药学进展》 CAS 2006年第8期341-349,共9页 Progress in Pharmaceutical Sciences
基金 上海市科学技术委员会科研计划项目课题(04DZ05902 04JC14068)
关键词 脂烯酰基酰基载体蛋白还原酶抑制剂 抗菌剂 作用机制 结构修饰 构效关系 Enoyl-acyl carrier protein reductase inhibitor Antibacterial Mechanism of action Structure modification Structure-activity relationship
  • 相关文献

参考文献16

  • 1Heath R J,White S W,Rock C O,et al.Lipid biosynthesis as a target for antibacterial agents[J].Prog Lipid Res,2001,40(6):467-497.
  • 2Heath R J,Li J,Roland G E,et al.Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene[J].J Biol Chem,2000,275(7):4654-4659.
  • 3Parikh S,Moynihan D P,Xiao G,et al.Roles of tyrosine 158 and lysine 165 in the catalytic mechanism of InhA,the enoyl-ACP reductase from Mycobacterium tubercu-losis[J].Biochemistry,1999,38(41):13623-13634.
  • 4Heath R J,Rock C O.A triclosan-resistant bacterial enzyme[J].Nature,2000,406(6792):145-146.
  • 5Heath R J,Su N,Murphy C K,et al.The enoyl-[acylcarrier-protein] reductases FabI and FabL from Bacillus subtilis[J].JBiol Chem,2000,275(51):40128-40133
  • 6Payne D J,Warren P V,Holmes D J,et al.Bacterial fattyacid biosynthesis:a genomics-driven target for antibacterial drug discovery[J].Drug Discov Today,2001,6(10):537-544.
  • 7McDevitt D,Payne D J,Holmes D J,et al.Novel targets for the future development of antibacterial agents[J].J Appl Microbiol,2002,92(Suppl):28S-34S.
  • 8Levy C W,Roujeinikova A,Sedelnikova S,et al.Molecular basis of triclosan activity[J].Nature,1999,398(6726):383-384.
  • 9Heath R J,Rubin J R,Holland D R,et al.Mechanism of triclosan inhibition of bacterial fatty acid synthesis[J].J Biol Chem,1999,274(16):11110-11114.
  • 10Heerding D A,Chan G,DeWolfW E Jr,et al.1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI)[J].Bioorg Med Chem Lett,2001,11(16):2061-2065.

同被引文献17

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部